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Abstract
Leukaemic stem cell (LSC) persistence remains a major obstacle to curing chronic myeloid leukaemia (CML). The bone
morphogenic protein (BMP) pathway is deregulated in CML, with altered expression and response to the BMP ligands
shown to impact on LSC expansion and behaviour. In this study, we determined whether alterations in the BMP
pathway gene signature had any predictive value for therapeutic response by proﬁling 60 CML samples at diagnosis
from the UK SPIRIT2 trial and correlating the data to treatment response using the 18-month follow-up data. There was
signiﬁcant deregulation of several genes involved in the BMP pathway with ACV1C, INHBA, SMAD7, SNAIL1 and SMURF2
showing differential expression in relation to response. Therapeutic targeting of CML cells using BMP receptor
inhibitors, in combination with tyrosine kinase inhibitor (TKI), indicate a synergistic mode of action. Furthermore, dual
treatment resulted in altered cell cycle gene transcription and irreversible cell cycle arrest, along with increased
apoptosis compared to single agents. Targeting CML CD34+ cells with BMP receptor inhibitors resulted in fewer cell
divisions, reduced numbers of CD34+ cells and colony formation when compared to normal donor CD34+ cells, both
in the presence and absence of BMP4. In an induced pluripotent stem cell (iPSC) model generated from CD34+
hematopoietic cells, we demonstrate altered cell cycle proﬁles and dynamics of ALK expression in CML-iPSCs in the
presence and absence of BMP4 stimulation, when compared to normal iPSC. Moreover, dual targeting with TKI and
BMP inhibitor prevented the self-renewal of CML-iPSC and increased meso-endodermal differentiation. These ﬁndings
indicate that transformed stem cells may be more reliant on BMP signalling than normal stem cells. These changes
offer a therapeutic window in CML, with intervention using BMP inhibitors in combination with TKI having the
potential to target LSC self-renewal and improve long-term outcome for patients.
Introduction
Chronic myeloid leukaemia (CML) treatment involves
targeting BCR-ABL to prevent its tyrosine kinase activity.
TKIs effectively target progenitor cells, however leukaemic
stem cell (LSC) are more quiescent and less sensitive to
treatment1–5. Studies of CML patients on imatinib mesylate
(IM) treatment for >4 years indicate BCR-ABL+ cells are
retained in the primitive CD34+ CD38− population, even
when a deep molecular response is achieved, thus CML
LSC are not eradicated6,7. Recent clinical trials ‘The Stop
Imatinib 1 (STIM1) and the STOP 2G-TKI Study’ are very
encouraging with 38% and 43% of patients, respectively,
sustaining long-term molecular responses when TKI was
discontinued8,9. For many patients, TKI treatment alone is
insufﬁcient to cure CML, even when a sustained deep
molecular response has been achieved, highlighting differ-
ent pathophysiology for some patients.
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Interest has therefore focused on developing new
treatments to use in combination with TKI, thereby
improving the number of patients who can discontinue
treatment in the future without relapse. A feasible therapy
approach would involve combining TKI with compounds
to target alternative survival mechanisms, such as self-
renewal pathways involved in HSC maintenance in the
bone marrow (BM) niche and deregulated in CML10–13.
These embryonic morphogenic pathways have a key role
in hematopoiesis, with evidence suggesting LSCs hijack
them to their advantage, making the BM microenviron-
ment more suitable for their survival and proliferation14.
The TGFβ superfamily, including the bone morpho-
genic proteins (BMP) are important for sustaining BM
homoeostasis. Transcriptome studies of CML LSCs and
progenitors indicate that the TGFβ and BMP ligands are
downregulated in chronic phase (CP)-CML, suggesting an
extrinsic mechanism for TGFβ involvement in this dis-
ease15. Intriguingly, the BMP type I receptors, especially
BMBR1B are overexpressed in CML LSCs, whereas
SMAD1, BMP2 and BMP4 are downregulated16. Sup-
porting our published microarray data17, which conﬁrms
that the BMP pathway and downstream signalling mole-
cules are signiﬁcantly deregulated in CP, accelerated
phase (AP) and blast crisis (BC) CML in both primitive
LSCs and progenitor subpopulations. These ﬁndings
suggest CML LSCs may change their reliance/response to
the BMP/TGFβ superfamily, especially as the disease
progresses from CP to AP/BC17. This is supported by a
study showing signiﬁcantly higher levels of BMP2 and
BMP4 ligands are present in CML patients’ BM, com-
pared to normal donors. Moreover, CP-CML early pro-
genitors express higher levels of type I receptors, making
them more responsive to the increased levels of soluble
BMP2 and BMP4 in the leukaemia BM niche, resulting in
expansion. CML LSCs, when cultured in the presence of
BMP2 or BMP4, maintained their primitive phenotype
with enhanced long-term colony-forming potential16.
LSCs from TKI-resistant patients also express higher
levels of BMPR1B, BMP4 and TWIST1 with treatment
preferentially selecting survival of BMPR1BHi cells within
the immature population. Mesenchymal stem cells (MSC)
from these patients also displayed higher levels of
BMP4 secretion18. These data indicate that alterations in
the BMP pathway may suppress differentiation and
potentiate the survival of a permanent autonomous pool
of LSCs in CP-CML.
In this study, we evaluate the BMP pathway and down-
stream targets in 60 CP-CML patients at diagnosis. These
ﬁndings were correlated to treatment response to identify
a subset of genes differentially expressed between good/
intermediate/poor responders to treatment. We demon-
strate targeting the BMP receptors (ALKs) in combination
with IM is synergistic, resulting in irreversible cell cycle
arrest and increased apoptosis of CML cells. Furthermore,
CML CD34+ cells display greater sensitivity to BMP path-
way inhibition than normal CD34+ cells, undergoing fewer
cell divisions, with reduced CD34+ cells numbers and col-
ony formation occurring following treatment. Furthermore,
CML-iPSCs express higher levels of ALKs than normal
iPSCs and are more sensitive to ALK inhibition, resulting in
a reduced capacity to self-renew. Overall, our ﬁndings
indicate a potential therapeutic window whereby dual
treatment with TKI and ALK inhibitors could selectively
target CML stem cells.
Results
The BMP/SMAD pathway is deregulated in CP-CML
To characterise the BMP pathway, we analysed 60
CP-CML samples from the UK-based SPIRIT2 trial. A
signiﬁcant number of BMP-related genes were differ-
entially expressed (Fig. 1a) in CML. Relative to normal
controls, BMP2, TGFβ1, AVCR1 (ALK2), BMPR1A
(ALK3), SMAD1 and SMAD2 showed opposite expres-
sion patterns when comparing the more primitive CML
CD34+ population to the more mature MNCs. However,
ACVR1B (ALK4), BMPR1B (ALK6), ACVRIC (ALK7),
ACVR2A, SMAD5 SMAD6, RUNX1 and RUNX2 showed
the same expression pattern in both populations. Using
the 18-month follow-up data, patients were stratiﬁed
into optimal, warning and treatment failure categories
(termed “good/intermediate/poor TKI responders”)
according to the European LeukemiaNet 2013 TKI
response criteria19. We tracked gene expression patterns
to clinical response, to identify a gene signature for TKI-
responders vs non-responders (Fig. 1b and Table 1). In
CD34+ samples, three genes ACVR1C, INHBA, SMAD7,
and in MNC samples, four genes SMAD1, INHBA,
SMURF2 and SNAIL1 showed signiﬁcant differential
expression in the good/intermediate/poor TKI respon-
ders. Interestingly, INHBA was the only gene upregu-
lated in both the CD34+ and MNC intermediate/poor
responders, this correlates with our previous data,
indicating that INHBA is signiﬁcantly upregulated in
BC-CML LSC when compared to CP, and AP LSC, and
normal HSC17 (GEO:GSE47927).
ALK inhibitors act synergistically with IM
Next we inhibited BMP signalling using two ALK
inhibitors, LDN and DOR20,21. IC50 values determined
from XTT assays and trypan blue exclusion experiments
were used to set up combination drug analyses with IM in
K562 cells. Synergy calculations performed using Calcu-
Syn. Both LDN and DOR act synergistically with IM
(Fig. 2a), with combination treatment more effective at
eradicating leukaemic cells than single agents. Speciﬁcity
of action was conﬁrmed by immunoblotting (Fig. 2b) with
dual inhibition signiﬁcantly reducing phosphorylation of
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BCR-ABL, CrKL and STAT5. DOR and LDN both
inhibited the BMP pathway with reduced pSMAD1/5/8
(R-SMADs) observed ±BMP4 (Fig. 2b, c); IM had no
effect. Treatment of CD34+ CP-CML cells with LDN or
DOR ±IM resulted in downregulation of BMP-related
genes, especially the SMAD and SMURF family of genes.
Interestingly Activin A and it’s receptor BMPR1A (ALK3)
were upregulated following inhibition especially following
IM/DOR treatment, this was accompanied by upregula-
tion of SMAD7 an Activin A inducible gene, which is a
potent antagonist of TGFβ1 signalling (Fig. 2d).
The impact of targeting the BMP pathway on the cell cycle
BCR-ABL is a potent driver of cell cycle, with IM
causing G1 cell cycle arrest in CML. To ascertain the
status of key genes involved in G1-S progression, we
proﬁled the SPIRIT2 samples. Fig 3a clearly demonstrates
important drivers of G1-S phase transition such as
CyclinE and CDK2 are upregulated in CP-CML. Inter-
estingly, CML MNC express signiﬁcantly higher levels of
cell cycle genes than normal donors, indicative of the
more immature/proliferative nature of the BCR-ABL-
transformed cells. Using pathway analysis software, we
mapped the links between BMP signalling and cell cycle
in CML using gene proﬁling data (Figure S1).
BMP signalling upregulates the inhibitor of differentia-
tion/DNA binding (ID) family of early response genes22.
BCR-ABL also induces ID1 with high levels observed in
CML22,23. ID expression is necessary for re-entry of
quiescent cells into the cell cycle and G1-S progression24.
Next, we ascertained whether treatment of CD34+ cells
with IM alone and in combination with BMP inhibitors
Fig. 1 BMP pathway gene expression is deregulated in CP-CML and is associated with TKI response. a The BMP pathway and its downstream
genes were analysed in 30 CP-CML CD34+ samples (stem/progenitor population) and 30 MNC CP-CML samples from the SPIRIT2 clinical trial using
the Fluidigm Biomark system. Four normal CD34+ BM samples, two peripheral blood CD34+ normal donor samples and four normal MNC samples
were used as comparators. Statistical analysis was performed using Welch’s test. b SPIRIT2 sample follow-up in CD34+ and MNC samples from ELN
optimal, warning and failure patients. Analysis was performed by comparing the expression of each gene in poor, intermediate and good responders
to the normal donors. Statistical analysis was performed using Student’s paired t-test. **p < 0.01–0.001, *p < 0.05–0.01
Toofan et al. Cell Death and Disease  (2018) 9:927 Page 3 of 19
Ofﬁcial journal of the Cell Death Differentiation Association
affected ID1 expression. As shown, IM reduced the
expression of ID1 compared to NDC with expression
further reduced in the combination approach (Fig. 3b).
Cell cycle progression analysis showed DOR was more
effective than LDN at perturbing progression in K562
cells (Fig. 3c). Treatment with IM or DOR arrested CML
cells in G0-G1 phase, accompanied by a reduction in S/
G2M (Fig. 3c–i). This increased with dual inhibition
(Fig. 3c–ii). Assessment of cell cycle after dual IM/DOR
treatment for 24 h followed by wash-out, indicates cell
cycle arrest is irreversible (Fig. 3d–i). Gene proﬁling
shows IM reduces the expression of CDK genes at 24 h
with DOR having minimal effect at this time point
(Fig. 3d–ii). Following treatment and wash-out, IM
reduced the expression of CCNA1, CCNA2, CDC25A,
CDC25B, E2F3 and E2F6 with dual inhibition (IM and
DOR) further reducing expression (Fig. 3d–ii). Cell cycle
analysis of CML CD34+ cells, revealed they were more
sensitive to all treatment arms than normal CD34+, with a
signiﬁcant increase in cells in sub-G0 following dual
treatment with LDN+ IM, DOR alone and DOR+ IM
(Fig. 3e–ii). Similar results were obtained in the presence
of BMP4 stimulation (Fig. S2A), with no changes when
CD34+ were co-cultured on the stromal cell line HS5
Fig. 2 (See legend on next page.)
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(Figure S2B). Comparison of all the cell cycle data
(Fig. S2C & D) indicates co-culture has a protective effect
on CD34+ cell cycle arrest, preventing them from enter-
ing Sub-G0 following ALK inhibition. Important cell cycle
genes also changed (Fig. 3f), with downregulation of
CDC25A, CDC25B and CDC25C. CDKN1B, CDK6, ATM
and TP53 enhanced when IM and ALK inhibitors were
combined.
Dual inhibition results in increased apoptosis
To measure apoptosis, Annexin V/7AAD assays were
performed in K562 (Fig. 4a), normal and CP-CML CD34+
cells (Fig. 4b). Inhibition of BCR-ABL and ALKs shifted
CML cells into apoptosis. Results were more profound in
IM+ALK inhibitor combination arms, with signiﬁcantly
higher levels of apoptosis observed in the CML CD34+
(Fig. 4b–ii, S3E) when compared to normal CD34+ cells
(Fig. 4b–i, S3E). Similar results were observed in the pre-
sence of BMP4 stimulation (Fig. 4b–iii, iv & S3B). Co-
culture on HS5 protected CD34+ cells from undergoing
apoptosis in response to treatment (Fig. S3C–E). Higher
levels of apoptosis occurred at 72 h in the NDC for normal
and CML CD34+ cells co-cultured on HS5 (Fig. S3C–E),
this is due to the increased proliferation observed, with on
average a twofold expansion of cell numbers when com-
pared to culture on plastic ±BMP4 at 72 h.
ALK inhibition reduces CML CD34+ cell division and
numbers
To determine what effects BMP pathway inhibition had
on cell division and overall CD34+ cell numbers, CD34+
cells were labelled with CellTrace™ Violet (CTV) and an
APC-conjugated anti-CD34 antibody. Following 72 h drug
treatment, proliferation and CD34-positivity were asses-
sed by ﬂow cytometry. Figure 5a & S4B clearly demon-
strate that both normal and CML CD34+ cells are
sensitive to DOR treatment, undergoing less cell divisions
than NDC. CML CD34+ cells displayed enhanced
sensitivity, responded to all treatment arms with more
cells accumulating in CTVmax and early divisions than
observed for normal CD34+, with the most dramatic
effects observed within the DOR, IM+ LDN and IM+
DOR treatment arms (Fig. 5a–ii and S4B). Similar results
were observed in the presence of BMP4 stimulation
(Fig. 5b and S4C). Although BMP4 stimulation did not
alter the capacity to divide, untreated CML cells under-
went a 20.5% ± 12.6% (n= 3) expansion in CD34+ num-
bers following BMP4 stimulation, with no change
observed in normal CD34+ numbers (Figure S4E–iii),
conﬁrming CML cells are more responsive to BMPs16.
Co-culture on HS5 rendered the drugs less effective,
however CML cells still accumulated in CTVmax and
division 1 following DOR, IM+ LDN and IM+DOR
treatment, indicating the BMP inhibitors were still eli-
citing an effect albeit to a reduced capacity (Figure S4A &
D). Figure 5c and S4E clearly demonstrate that IM, LDN
and DOR lead to a reduction in CML CD34+ cells, with
the biggest reduction observed following DOR, IM+
LDN and IM+DOR treatment. To determine what
effects inhibition had on CML cell expansion and differ-
entiation along the different hematopoietic lineages, CFC
assays were performed. In CML, CFCs were signiﬁcantly
decreased in all treatment arms with less colonies
observed following combination treatment (Fig. 5d–ii, iii)
with no signiﬁcant effects on normal CD34+ (Fig. 5d–i).
These ﬁndings indicate viable CML cells surviving 72 h of
dual treatment are unable to proliferate and differentiate
to the same capacity compared with IM alone, indicating
BMP inhibitors may act synergistically with IM to target
CML cells through irreversible cell cycle arrest and
apoptosis.
CML-iPSC are reliant on the BMP pathway for their self-
renewal
To investigate whether CML stem cells are more
dependent on the BMP pathway than their normal
(see ﬁgure on previous page)
Fig. 2 IM and BMP pathway inhibitors synergistically target the K562 CML cell line. a Synergy studies of the BMP pathway inhibitors, LDN-
193189 (LDN) and Dorsomorphin (DOR) with imatinib mesylate (IM) were performed using CalcuSyn to quantify additive, synergistic and inhibitory
effects. Tables present the fraction of cells affected (Fa) and combination index (CI) values at different combination concentrations. The bottom table
describes the correlation between CI range and synergism. As shown, both LDN and DOR, in combination with IM, synergistically induce cell death in
K562 cells. b Protein analysis of K562 cells treated with IM, BMP inhibitors and the combination (IM= 500 nM, LDN= 500 nM, DOR= 2.5 μM, n= 3)
compared to no-drug control (NDC) using western blot hybridisation following drug treatment in the presence and absence of BMP4 stimulation.
i IM and LDN combination immunoblots at 4 h (left panel) and IM and DOR combination immunoblots at 4 h (right panel). K562 cells were stimulated
with 20 ng/mL BMP4 for 30 min; this was followed by drug treatment. SHP2 was used as the housekeeping protein. ii Densitometry analysis of
western blots was performed using image J software. Analysis was normalised relative to the housekeeping protein expression. Both BMP inhibitors
synergistically inhibit pCrKl signiﬁcantly in the absence of BMP4 stimulation. Data are expressed as mean ± standard deviation and were compared
using the unpaired Student’s t-test, *p < 0.05; n= 4. c Protein analysis using immunoﬂuorescence in K562 cells treated with IM, BMP inhibitors and
the combination of both (n= 3) at 24 h ± BMP4 stimulation. Panels of four pictures for each treatment include a single staining for SMAD1/5/8 in
green, SMAD4 in red, the combination of both as the merge and no antibody in DAPI blue. d CD34+ primary CP-CML samples (n= 4) were treated
with IM, BMP inhibitors and the combination of both (IM= 1 µM, LDN= 1 µM, DOR= 2.5 μM). Expression of BMP pathway genes was assessed at
72 h using the Fluidigm Biomark system; data were normalised to untreated cells
Toofan et al. Cell Death and Disease  (2018) 9:927 Page 5 of 19
Ofﬁcial journal of the Cell Death Differentiation Association
counterparts, we utilised iPSC models. We generated
iPSCs from CD34+ selected cells from normal donors and
CP-CML patients (Fig. 6a). All six lines demonstrate
typical characteristics of pluripotent stem cells; compact
morphology, strong alkaline phosphatase (APh) activity,
high expression of key pluripotency transcription factors
and pluripotent cell surface markers. FISH analysis con-
ﬁrmed the presence of the Philadelphia chromosome in
the three CML-iPSCs lines (Fig. 6a, b). Similar to CML
CD34+ cells, gene proﬁling indicate components of the
BMP pathway were differentially expressed in CML-iPSCs
compared to normal iPSCs, with BMP2 strongly down-
regulated and SMURF1 strongly upregulated (Fig. 6c).
To check the ability of normal and CML-iPSCs to
respond to BMP ligands, we analysed AVCR1 (ALK2),
BMPR1A (ALK3) and BMPR1B (ALK6) expression
±BMP4 stimulation by FACS. CML-iPSCs expressed sig-
niﬁcantly higher levels of AVCR1 (ALK2) and BMPR1A
(ALK3) receptors than normal iPSCs, with high levels of
BMPR1B (ALK6) expressed by both (Fig. 6d–i).
Fig. 3 (See legend on next page.)
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Treatment with IM, BMP inhibitors or in combination,
±BMP4 stimulation, resulted in a signiﬁcant reduction in
AVCR1 (ALK2) expression (Fig. 6d–ii), with no changes
in BMPR1A (ALK3) and BMPR1B (ALK6) (data not
shown) in CML-iPSCs. Treatment had no effect on nor-
mal iPSCs (data not shown). Cell cycle analysis revealed
altered proﬁles in CML-iPSCs compared to normal iPSCs
with fewer cells in the sub-G0 stage and more in G0-G1
Fig. 3 The effect of IM and BMP inhibitors on cell cycle progression and cell cycle gene expression pattern. a Cell cycle pathway gene
expression of 60 patients enrolled in the SPIRIT2 clinical trial. Genes were analysed in 30 CP-CML CD34+ samples and 30 MNC CP-CML samples using
the Fluidigm Biomark system. Four normal CD34+ BM samples, two peripheral blood CD34+ normal donor samples and four normal MNC samples
were used as comparators. Statistical analysis was performed using Welch’s test. b The expression level of ID was assessed in CD34+ cells treated with
IM, BMP inhibitors and the combination. Dual inhibition with both BMP inhibitors and IM decreased the expression of ID in all patient samples tested,
compared to single-agent treatments. Statistical analysis was performed using Student’s paired t-test. *p < 0.05–0.01. c Propodium iodide (PI) analysis
of cell cycle progression in K562 cells treated with IM, BMP inhibitors and the combination of both (IM= 500 nM, LDN= 500 nM, DOR= 2.5 μM, n=
4) after 72 h. i Treatment with individual inhibitors arrested cells in G1, with DOR causing more cell cycle arrest than LDN or IM. ii There is a further
increase in the number of cells present in G1 phase when DOR was used in combination with IM (n= 4). d-i PI analysis of K562 cell cycle treated with
IM, BMP inhibitors and the combination (IM= 500 nM, LDN= 500 nM, DOR= 2.5 μM, n= 3) when cells are washed to remove drugs 24 h post
treatment. IM arrests K562 cells in G0-G1 at 24 h; however, cells go back into cycle after drug withdrawal. A different pattern was observed with DOR
in combination with IM, where cells remained out of cycle after drug removal with a signiﬁcant increase in the number of cells present in sub-G1.
ii Expression analysis of cell cycle genes 48 h after drug wash-out, n= 3. e Cell cycle analysis of normal and CP-CML CD34+ samples treated with IM,
BMP inhibitors and the combination of both (IM= 1 µM, LDN= 1 µM, DOR= 2.5 μM) at 72 h. Data show a signiﬁcant increase in the number of cells
in Sub-G0 in all single and dual treatments of normal and to a higher extent for CML samples (n= 3) (f) Analysis of cell cycle genes in CD34+ CP-CML
cells in response to treatments (IM= 1 µM, LDN= 1 µM, DOR= 2.5 μM, n= 4). Cell cycle PI data are expressed as mean ± standard deviation and
were compared using the unpaired Student’s t-test (c, d) or ANOVA (e). ****p < 0.0001, ***p < 0.001–0.0001, **p < 0.01–0.001, *p < 0.05–0.01
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Fig. 4 IM and BMP inhibitors induce apoptosis in CML cells. a Annexin V/ 7AAD apoptosis analysis of K562 cells treated with IM, BMP inhibitors
and the combination (IM= 500 nM, LDN= 500 nM, DOR= 2.5 μM, n= 3) at 72 h. i Inhibition of BCR-ABL and BMP pathway results in apoptosis, and a
reduction in viable cells. ii Results are signiﬁcantly more profound when IM is used in combination with DOR with more cells in early apoptosis (n=
3). b Annexin V/7AAD apoptosis analysis of normal and CP-CML CD34+ cells treated with IM, BMP inhibitors and the combination (IM= 1 µM, LDN=
1 µM, DOR= 2.5 μM, n= 3) at 72 h. i, ii Results indicate that IM in combination with BMP pathway inhibitors promote modest, but signiﬁcant,
apoptosis in normal CD34+ cells. However, apoptosis is greatly increased in CP-CML CD34+ samples. This is reﬂected in the increased number of
cells present in late apoptosis (n= 3). iii, iv Inhibitor treatments with addition of BMP4 also indicate a signiﬁcant increase of normal and CP-CML
CD34+ cells in late apoptosis, with more apoptosis observed in the CML CD34+ samples (n= 3)
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±BMP4 stimulation (Fig. 6e). BMP signalling is important
for controlling cell cycle, we therefore assessed the effects
of single and dual treatments on cell cycle,
±BMP4 stimulation in our iPSC model of CML. Following
72 h treatment, no signiﬁcant changes in the cell cycle
proﬁle occurred regardless of drug treatment or
BMP4 stimulation (Figure S5A). To assess signalling
pathways affected by BCR-ABL, we monitored the phos-
phorylation of pCrkL by immunoblotting following 4 h of
treatment ±BMP4 stimulation in normal and CML-iPSCs
(Fig. 6f–i). As expected, normal iPSCs have very low levels
of CrkL with no change in phosphorylation observed
following drug treatments or BMP4 stimulation. Whereas
CML-iPSCs had high levels of pCrkL, which was
Fig. 5 (See legend on next page.)
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signiﬁcantly reduced following IM and DOR treatment.
Densitometry analysis indicated IM+DOR had a syner-
gistic effect on reducing pCrkL levels (Fig. 6f–ii).
A fundamental property of iPSCs is their ability to self-
renew. Live APh staining was used to monitor pluripotent
state in CML- and normal iPSCs treated with single and
dual therapies for 72 h (Fig. 7a). APh stain intensity
(green) was compared to total stain (orange); NDC sample
was used as a comparator in each set. CML-iPSCs dif-
ferentiated more than normal iPSCs when treated with
IM and ALK inhibitors. This effect was more evident
when colonies were treated with IM alone or in combi-
nation with DOR (Fig. 7b) especially following longer
drug treatments (Figure S5B–i, ii) with dual inhibition
more effective at reducing the pluripotency of CML-
iPSCs. Single and dual inhibition also caused reduction in
the expression of important pluripotency genes in CML
colonies only, with all the genes assessed reduced by dual
inhibition (Fig. 7c). Analysis of key differentiation genes
indicate cells are primed to undergo meso-endodermal
differentiation with ACTC1, MESP1 and PODXL all being
upregulated following dual inhibition of CML-iPSCs
(Fig. 7d). Overall these results indicate that CML-iPSC
depend more on BMP signalling to sustain their stem cell
properties than normal iPSC.
Discussion
In CML, minimal residual disease persists in many
patients on TKIs, with a high level of relapse occurring
if TKI is withdrawn8,9. Therefore, additional kinase-
independent mechanisms involved in LSC persistence
need to be identiﬁed and targeted if treatment-free
Fig. 5 Single treatment of DOR and dual treatments of BMP inhibitors and IM inhibit cell proliferation of CML CD34+ cells. a, b CellTrace™
Violet (CTV) proliferation analysis of normal and CP-CML CD34+ cells treated with IM, BMP inhibitors, the combination (IM= 1μM, LDN= 1 μM, DOR
= 2.5 μM, n= 3), in absence or presence of BMP4 at 72 h. i Results for normal CD34+ cells display that single and dual treatment of IM+ DOR inhibit
cell proliferation, and additional BMP4 treatment (b) results in more cell divisions compared to standard culture conditions without BMP4.
a-ii Proliferation analysis of CP-CML samples indicates that LDN in combination with IM synergistically inhibits proliferation compared to single
treatment. DOR alone and in combination with IM displays the biggest fold change compared to NDC. Additional treatment with BMP4 (b-ii) did not
reveal differences in proliferation progression compared to standard culture conditions. c IM and BMP inhibitors reduce CD34+ cell numbers in CP-
CML samples in absence or presence of BMP4. Results are displayed as median range of CD34+ cell numbers of normal and CP-CML CD34+ cells
treated with IM, BMP inhibitors and the combination (IM= 1 µM, LDN= 1 µM, DOR= 2.5 μM, n= 3) in absence or presence of BMP4. d-i CFC assay
results of normal CD34+ cells treated with IM, BMP inhibitors and the combination of (IM= 1 µM, LDN= 1 µM, DOR= 2.5 μM) do not reveal any
signiﬁcant difference compared to NDC (n= 3). ii Total number of colonies of CP-CML CD34+ cells display a signiﬁcant difference across all
treatments compared to NDC and a synergistic reduction when IM and DOR were used in combination (n= 3). iii CFC results of K562 cells. Results
also indicate a signiﬁcant drop in the number of colonies with IM, DOR and LDN. Results are also reﬂected in the morphology of the colonies with
DOR and LDN treatment reducing the size of colonies (n= 3). Data are expressed as mean ± standard deviation and were compared using ANOVA (c)
and the unpaired Student’s t-test (a, b, d), ***p < 0.001–0.0001, **p < 0.01–0.001, *p < 0.05–0.01
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remission is to be achieved. Recent evidence indicates that
some of the important regulatory networks involved in
establishing primitive and deﬁnitive hematopoiesis during
development are reactivated in leukaemias, giving rise to a
LSC population with altered self-renewal and differ-
entiation properties25. One pathway warranting further
investigation is BMP signalling. BMPs are fundamentally
important for osteoblast differentiation26,27, self-renewal
and maintenance of HSCs, and expansion and differ-
entiation of progenitor cells into mature hematopoietic
cells28–31. Previously, we and others highlighted that the
BMP pathway was deregulated in CML15,17. Furthermore,
an earlier study demonstrated higher than normal levels
of BMP ligands in the BM of CML patients and enhanced
expression of BMPR1B receptor by CP-CML CD34+, with
BMP2 or BMP4 stimulation, maintaining their primitive
Fig. 6 (See legend on next page.)
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phenotype16. Data from the same group demonstrated
that high BMPR1B and TWIST1 expression is linked to
treatment resistance and disease progression32, with
treatment resulting in upregulation of TWIST1 and
selecting for survival of BMPR1BHi cells18. Furthermore,
the LSC and MSC populations from these patients
expressed higher levels of BMP4. In LTC-IC assays per-
formed on BMPR1BHi and BMPR1BLo LSC, more LTC-IC
were present in the presence of BMP2/4 and following IM
and IM/IFNα treatment in the BMPR1BHi LSC, indicating
the BMP signalling pathway has an important role in LSC
maintenance and CML disease persistence18.
Components of the BMP pathway were signiﬁcantly
deregulated in both CD34+ cells and MNCs from CP-
CML SPIRIT2 samples. In CD34+ cells, BMP2 was
downregulated, whereas type 1 receptors AVCR1 (ALK2),
BMPR1B (ALK6), TGFβΡ1 and several of the SMAD genes
were upregulated. In contrast, BMP2 transcript was
upregulated in MNC along with BMPR1A (ALK3),
BMPR1B (ALK6) and SMADs. These ﬁndings support
previous ﬁndings showing BMP2 is produced by the
mature CML polymorphonuclear cells, and CML CD34+
cells are likely to have potentiated signalling in response
to ligand16. TGFβ signalling is linked to poor TKI
response in CML, with enrichment of the pathway
observed at the single-cell level in poorly responding
BCR-ABL− and BCR-ABL+ CML cells33. TGFβ signals
through Foxo3A to confer apoptosis resistance in CML
LSC34. Also TGFα is a potential biomarker for predicting
patient response to TKI, with high levels in patient serum
at diagnosis correlating to a failure to obtain a major
molecular response35.
Fig. 6 Deregulation of the BMP pathway in CML-iPSC. a Schematic representation of generating iPSCs from treatment naive CP-CML and normal
samples using Sendai virus transduction of the reprogramming genes. i Experiment timeline for reprogramming CD34+ cells. ii A schematic
representation of Sendai virus reprogramming of CD34+ cells from CP-CML patients. iii The morphology of cells during reprogramming period from
single cells in suspension to iPSC colonies attached to matrigel coated plates. iv An iPSC colony with deﬁned edges and a compact core. iPSCs were
regularly passaged and colonies with highest pluripotency quality were plucked to help maintain this morphology. v Alkaline phosphatase (APh)
staining. vi The expression level of REX1, KLF4 and NANOG were assessed by PCR in all iPSCs. vii Immunoﬂuorescence staining with TRA1-60, SOX2,
OCT4 and SSEA4 was used to conﬁrm pluripotency at protein level in iPSCs. viii Fluorescent in situ hybridisation (FISH) conﬁrming the presence of
BCR-ABL translocation in CML-iPSC colonies. b qRT-PCR conﬁrming the expression of important pluripoptency genes in the three normal and three
CML-iPSC samples. c The expression level of BMP pathway components analysed using qRT-PCR in CML-iPSCs. Data were normalised relative to
normal-iPCSs. d-i Analysis of BMPRIs (ALK2, 3 and 6) in normal and CML-iPSCs using ﬂow cytometry. To stimulate BMP pathway, cells were treated
with 20 ng/mL BMP4 for 24 h prior to experiment. CML-iPSCs express signiﬁcantly higher levels of ALKs 2 and 3 in the presence and absence of
BMP4 stimulation compared to normal samples. ii FACS analysis of ALK2 expression in CML and normal iPSCs following drug treatment. Results are
expressed relative to NDC. e Cell cycle analysis of normal and CML-iPSCs in the presence and absence of BMP4 stimulation. f-i Protein analysis of
pCrKL in normal and CML-iPSCs treated with IM, BMP inhibitors and the combination of both using immunoblotting ± BMP4 stimulation at 4 h.
SHPTP2 was used as a control. ii Statistical analysis of immunoblots shows that dual inhibition using IM and DOR has a synergistic effect on reducing
pCrKl levels in CML-iPSCs. Data are expressed as mean ± standard deviation and were compared using Anova and the unpaired Student t-test, ***p <
0.001–0.0001, **p < 0.01–0.001, *p < 0.05–0.01, n= 3
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Correlating our expression data to TKI response, three
genes (ACVR1C, INHBA and SMAD7) in the CD34+
samples, and four genes (SMAD1, INHBA, SMURF2 and
SNAIL1) in the MNC samples, showed signiﬁcant differ-
ential expression between the good/intermediate/poor
responders. INHBA was more highly expressed in the
poor response group, and is highly expressed in BC-
CML17. Treatment of K562 with IM and the BMP path-
way inhibitors also resulted in upregulation of Activin A
and its receptor along with SMAD7 an Activin A indu-
cible gene, which is a potent TGFβ1 antagonist. Inter-
estingly, high levels of INHBA, correlates inversely with
survival in solid tumours36,37 and is linked to immuno-
suppression38. In multiple myeloma, high levels of Activin
A correlates with disease progression due to its role in BM
niche remodelling through osteolysis39. Activin A via
non-canonical SMAD2 signalling can also activate β-
catenin leading to upregulation of the TCF/LEF
transcriptional regulators38, a pathway well described in
CML progression and TKI resistance40. These ﬁndings
indicate an important role for BMP/TGFβ superfamily in
the pathogenesis of CML and a potential switch from
BMP to Activin A signalling in treatment resistance and
progressive disease.
Cell cycle deregulation is well documented in CML41–43,
with BMP signalling important for G1-S progression44.
Targeting the BMP pathway in combination with TKI
in CML resulted in cell cycle arrest, apoptosis and
altered target gene expression. Moreover, cell division
analysis revealed that DOR prevents CML CD34+ from
dividing and reduces the total number of CD34+ cells, with
similar results observed in the IM+DOR treatment arm.
Total CFC counts also illustrate that the combination
treatment had a more potent effect on long-term CML cell
survival and colony formation than single-agent treatment.
Analysis of normal CD34+ cells revealed signiﬁcantly
Fig. 7 (See legend on next page.)
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less sensitivity to the BMP pathway inhibition, indicating
a potential therapeutic window to target this pathway
in CML. Importantly, given the high BMP4 concentrations
in the BM, inhibition of the pathway still occurred
following BMP4 stimulation using both BMP pathway
inhibitors.
We generated iPSCs as a stem cell model, the rationale for
this approach was that pluripotent stem cells rely on the
BMP pathway for self-renewal45–47 and the BMP pathway is
important throughout HSC ontogeny, with recent evidence
indicating that the ﬁrst deﬁnitive HSC which arise during
development are BMP-primed48. This enables HSCs to
Fig. 7 Effect of inhibiting the BMP pathway on CML-iPSC self-renewal. a Monitoring the pluripotency level of normal (left panel) and CML (right
panel) iPSCs treated with IM, BMP inhibitors or the combination of both (IM= 1 µM, LDN= 1 µM, DOR= 2.5 µM) at 72 h using live APh staining.
Pictures were taken by IncuCyte live imaging system. Green ﬂuorescent tag illustrates APh positive cells. Orange ﬂuorescent tag stains all of the
colonies. b Comparison of surface area expressing APh in CML-iPSCs vs normal. Untreated sample was used as a comparator. Data are expressed as
mean ± standard deviation and were compared using Anova and the unpaired Student’s t-test, ***p < 0.001–0.0001, **p < 0.01–0.001, *p < 0.05–0.01,
n= 28 pictures for each arm. c Gene expression analysis shows a marked reduction in the expression of ALPL, NANOG and OCT3/4 in CML samples
only. d The expression of early differentiation genes assessed in CML-iPSCs when IM is used in combination with either BMP inhibitor. Data
normalised with untreated samples. e Schematic diagram demonstrating the potential role of ID1 in CML pathophysiology. Embryonic morphogenic
pathways and their downstream targets play key roles in the pathophysiology of CML, the early response gene ID1 could be an important
orchestrator in this process. ID1 upregulation occurs through BCR-ABL-dependent and independent mechanisms. ID1 expression is enhanced
through BCR-ABL-mediated STAT5 and SRC activation, with the ID1 promoter having a SRC-responsive element upstream of the translational start
site. BMP/SMAD signalling regulates ID1 through BRE in its promoter. Therefore, SRC can co-operate with SMAD to induce ID1 expression. Once
expressed, ID1 is known to mediate its effects by downregulating p53 and PTEN transcription, resulting in enhanced AKT phosphorylation and AKT-
mediated canonical Wnt signalling. ID1 can also enhance G1-S cell cycle progression and augment Hh and Wnt signalling through suppression of
CULLIN3, an ubiquitin ligase which targets CyclinE, GLI2 and DVL2 for degradation. BMP and Wnt pathways also converge to regulate the CDX family
of homeobox transcription factors, master regulators of HOX gene expression, important transcription factors involved in CML
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sustain their myeloid–lymphoid differentiation potential as
they migrate and expand within different anatomical sites
during development. However, by the time the HSCs
populate the BM, the majority are no longer BMP activated,
which could potentially reﬂect cell autologous changes or
the inﬂuence of the different extrinsic signals within the BM
microenvironment48. Reactivation of the pathway in CML
could therefore have important inﬂuences on stem cell
Table 1 Summary of statistical values for gene comparison between good/intermediate/poor TKI responders
p-Values CD34+
Clinical monitoring BCR-ABL ACVR1C INHBA SMAD7
3 months Good vs intermediate <1% vs 1–10% 0.0458 0.9172 0.9506
Good vs poor <1% vs >10% 0.0518 0.0170 0.9222
Intermediate vs poor 1–10% vs >10% 0.6752 0.0215 0.8824
Good vs intermediate/poor <1% vs >1% 0.0121 0.4609 0.9862
6 months Good vs intermediate <1% vs 1–10% 0.1489 0.2757 0.9659
Good vs poor <1% vs >10% 0.4402 0.5585 0.8917
Intermediate vs poor 1–10% vs >10% 0.7035 0.4079 0.8788
Good vs intermediate/poor <1% vs >1% 0.0915 0.9304 0.9547
9 months Good vs intermediate <0.1% vs 0.1–1% 0.1982 0.3637 0.0004
Good vs poor <0.1% vs >1% 0.0206 0.8899 0.7088
Intermediate vs poor 0.1–1% vs >1% 0.8047 0.4700 0.0260
Good vs intermediate/poor <0.1% vs >0.1% 0.0048 0.8645 0.1801
12 months Good vs intermediate <0.1% vs 0.1–1% 0.3331 0.9280 0.1183
Good vs poor <0.1% vs >1% 0.1792 0.8899 0.5539
Intermediate vs poor 0.1–1% vs >1% 0.9487 0.8535 0.4452
Good vs intermediate/poor <0.1% vs >0.1% 0.0745 0.9179 0.1932
18 months Good vs intermediate <0.1% vs 0.1–1% 0.7984 0.9093 0.3802
Good vs poor <0.1% vs >1% 0.00005 0.00001 0.0074
Intermediate vs poor 0.1–1% vs >1% 0.2686 0.0244 0.1939
Good vs intermediate/poor <0.1% vs >0.1% 0.1534 0.1755 0.8344
p-Values MNC
Clinical monitoring BCR-ABL SMAD1 INHBA SMURF2 SNAIL1
3 months Good vs intermediate <1% vs 1–10% 0.4601 0.4892 0.6416 0.0178
Good vs poor <1% vs >10% 0.0364 0.9185 0.3131 0.0912
Intermediate vs poor 1–10% vs >10% 0.21 0.5518 0.1129 0.8693
Good vs intermediate/poor <1% vs >1% 0.1602 0.6435 0.8190 0.0114
6 months Good vs intermediate <1% vs 1–10% 0.9672 0.5779 0.0405 0.9394
Good vs poor <1% vs >10% 0.7407 0.0500 0.1476 0.0008
Intermediate vs poor 1–10% vs >10% 0.7227 0.1227 0.2909 0.0568
Good vs intermediate/poor <1% vs >1% 0.9373 0.7969 0.0082 0.5516
9 months Good vs intermediate <0.1% vs 0.1–1% 0.9933 0.0294 0.1160 0.4770
Good vs poor <0.1% vs >1% 0.5802 0.9011 0.0382 0.7989
Intermediate vs poor 0.1–1% vs >1% 0.4988 0.0827 0.6998 0.4280
Good vs intermediate/poor <0.1% vs >0.1% 0.7022 0.4699 0.0137 0.9539
12 months Good vs intermediate <0.1% vs 0.1–1% 0.2131 0.0001 0.4544 0.1290
Good vs poor <0.1% vs >1% 0.3529 0.7514 0.0227 0.5460
Intermediate vs poor 0.1–1% vs >1% 0.0822 0.0281 0.8885 0.1894
Good vs intermediate/poor <0.1% vs >0.1% 0.9581 0.5950 0.0277 0.7893
18 months Good vs intermediate/poor <0.1% vs >0.1% 0.9690 0.6469 0.3967 0.6364
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behaviour, especially cell fate decisions. Cell cycle regulation
is tightly linked to pluripotency and stem cell fate. Here we
demonstrate that higher numbers of CML-iPSCs are in G0-
G1 compared to normal iPSCs, regardless of BMP4 stimu-
lation. This is important as this property in LSCs promotes
their quiescence even in the presence of TKI therapies.
Targeting the iPSC lines had no effect on cell cycle pro-
gression in the presence or absence of BMP4 stimulation.
However, our results indicate CML-iPSCs are sensitive to
IM treatment, reﬂected through their increased differentia-
tion when treated, highlighting a role for BCR-ABL in
the stemness properties of CML-iPSCs. Our protein
data correlates with previous studies, demonstrating phos-
phorylation of STAT5 and CrKL is signiﬁcantly decreased
after IM treatment49. Here we demonstrate that
IM and DOR combination treatment synergistically
reduces the phosphorylation of BCR-ABL and CrkL in
CML-iPSCs.
CML progenitors express higher levels of BMPRIs on
their surface16. Our iPSC data indicate CML-iPSCs also
have signiﬁcantly higher levels of ALK2 and ALK3 when
compared to normal iPSCs, which is sustained in the
presence of BMP4 stimulation. Inhibition of the BMP
pathway alone and in combination with BCR-ABL sig-
niﬁcantly decreases the expression level of AVCR1
(ALK2) in CML-iPSCs. More importantly, we demon-
strate that CML-iPSCs show a greater level of sensitivity
to the dual treatments, which result in loss of pluripotency
and increased differentiation when compared to normal
iPSCs. This was conﬁrmed by the upregulation of key
genes involved in meso-endodermal differentiation and
the downregulation of important pluripotency genes
including NANOG. These ﬁndings highlight how
deregulated BMP signalling in CML could lead to an
altered balance between self-renewal and differentiation.
BMP/SMAD signalling regulates early response genes
through BMP-responsive elements (BRE) in their pro-
moters, including ID1, important for development, cell
cycle G1 progression and tumorigenesis45,50. ID1 is upre-
gulated in CML22,51,52 and promotes proliferation and
migration50. ID1 expression is also enhanced through BCR-
ABL-mediated STAT5 activation51. The ID1 promoter has
a SRC-responsive element upstream of the translational
start site, with SRC co-operating with SMAD to induce its
expression53. Given that BCR-ABL interacts and activates
SRC kinases, ID1 upregulation through BCR-ABL depen-
dent and independent mechanisms is likely to have a key
role in CML pathophysiology. Our data clearly demonstrate
that IM reduces transcriptional levels of ID1 with further
reductions in the presence of LDN and DOR in both CML
CD34+ and CML-iPSCs. This has important implications as
ID1 is known to mediate its effects by downregulating p53
and PTEN transcription, resulting in enhanced AKT
phosphorylation and AKT-mediated canonical Wnt
signalling22. ID1 can also enhance G1-S cell cycle progres-
sion and augments Hh and Wnt signalling through sup-
pression of CULLIN3, an ubiquitin ligase, which targets
CyclinE, GLI2 and DVL2 for degradation54. The BMP and
Wnt pathways converge to regulate the CDX family of
homeobox transcription factors, master regulators of HOX
gene expression55,56. Given that deregulation of the Hh13,57
and Wnt57 pathways and the Hox axis57,58 have key roles in
CML, it is tempting to speculate that ID1 could be an
important orchestrator in this process (Fig. 7e).
Inhibiting type 1 BMP receptors with small-molecule
inhibitors, in combination with TKIs, is a promising
approach to deplete primitive CML stem/progenitor cells,
especially given the emerging role of BMP pathway signal-
ling in treatment resistance and disease relapse16,19. We
demonstrate that combination treatment caused irreversible
cell cycle arrest, increased apoptosis, reduced cell division
and survival of CD34+ cells in CML compared to normal
cells, with CML-iPSCs displaying less self-renewing poten-
tial and enhanced differentiation following therapy. Tar-
geting pathways CML cells depend on for self-renewal
especially BMP pathway is an attractive approach (Supple-
mental Table 1)59–64. Our results indicate a potential ther-
apeutic window in CML, with intervention using BMP
inhibitors in combination with TKI warranting further
investigation to prevent LSCs self-renewal and improve
treatment for patients in the future.
Materials and methods
Patient samples
Normal donors and CML samples were taken at
diagnosis following informed consent in accordance
with the Declaration of Helsinki, and approval of
the Greater Glasgow and Clyde National Health
Service. Samples were enriched for CD34+ cells using
the CliniMACS (Miltenyi Biotec) immunomagnetic
beads system. Cells were cryopreserved in 10% DMSO
(Sigma-Aldrich) and 5% human albumin solution
(Baxter Healthcare). SPIRIT2, a multicentre phase III
randomised trial (NCT01460693; clinicaltrials.gov), in
which CML patients were randomised into two groups,
to compare the TKIs, IM (400 mg daily) vs Dasatinib
(100 mg Daily). Sixty samples of cells were obtained
from the biobank in Glasgow (30 CD34+ puriﬁed from
peripheral blood, 30 MNC samples, 11 of which were
matched, i.e. both CD34+ and MNC available from the
same patients). Following thawing, RNA was extracted
using RNAEasy Micro kits (Qiagen) or Picopure RNA
isolation Kit (Thermo Fisher) to create an RNA bank of
samples. Reverse transcription using Superscript III
(Thermo Fisher) was then carried out to create cDNA
library from all of the samples. Normal BM CD34+ cells
were bought from Stem Cell Technologies and normal
CD34+ from peripheral blood were obtained from the
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Glasgow Biobank. Six normal CD34+ and four normal
MNC samples were used as comparators.
iPSC generation, maintenance and characterisation
CytoTune®-iPS Sendai Reprogramming Kit (Life Tech-
nologies) was used for iPSC generation from normal
CD34+ (Stem Cell Technologies) and treatment naive CP-
CML CD34+ cells as per manufacturer’s instructions
(Thermo Fisher). In brief, reprogramming was performed
as follows: CD34+ cells were cultured in StemSpan (Stem
Cell Technologies) media supplemented with 10% Mye-
locult (Stem Cell Technologies, BC, Canada), interleukin
(IL)-3 (10 ng/mL), IL-6, granulocyte-colony stimulating
factor (G-CSF), stem cell factor (SCF), Fms-like tyrosine
kinase-3 ligand (FLT3L), (all at 100 ng/mL) (PeproTech)
and 1% Penicillin/Streptomycin (Invitrogen, Paisley, UK)
for 2 days prior to viral transduction. hOCT3/4, hSOX2,
hKlf4, hC-MYC vectors were used at multiplicity of
infection (MOI)= 6. iPSCs, once generated, were cultured
in TeSR-E8 medium (Stem Cell Technologies) on matri-
gel (Corning)-coated Nunclon petri dishes (Fisher Scien-
tiﬁc) in feeder-free conditions. IPSCs were passaged using
EZ-Passage tool and DMEM/F12 Dulbecco’s Modiﬁed
Eagle Medium (Life Technologies) twice a week. Alkaline
phosphatase (APh) staining was used to assess plur-
ipotency (Sigma-Aldrich). Live APh staining was per-
formed using IncuCyte ZOOM Live Cell Imaging System
and software (Essen Bioscience). The expression level of
key pluripotency markers OCT4, SOX2, SSEA4, and/or
TRA-1-60 was detected using PSC 4-Marker Immuno-
cytochemistry Kit (Life Technologies) according to man-
ufacturer’s instructions.
Cell line and primary samples cell culture
K562 cells (DSMZ) were grown in RPMI 1640 (Sigma-
Aldrich) with 10% foetal calf serum, 1mM glutamine and
1% penicillin–streptomycin (Invitrogen). HS5 cells were
grown in DMEM (Gibco) with 10% fetal calf serum, 1mM
glutamine and 1% penicillin–streptomycin (Invitrogen). 24 h
prior to co-culture, HS5 were seeded on collagen coated
12-well plates at a cell density of 1.2 × 105 cells per well.
CD34+-enriched normal and CML cells were thawed
and cultured overnight in serum free media (SFM) (Life
Technologies) supplemented with; IL-3 (20 ng/mL), IL-6
(20 ng/mL), G-CSF (20 ng/mL), SCF and FLT3L (100 ng/mL)
(PeproTech). Prior to treatment with inhibitors, culture media
for CD34+ enriched cells was changed to more physiological
growth factor concentrations; IL-3 (0.2 ng/mL), IL-6
(0.2 ng/mL), G-CSF (0.2 ng/mL), SCF and FLT3L (1 ng/mL).
Inhibitors
Overall, 100mM stock solution of IM (Stratech) was
prepared in water and stored at 4 °C; BMP pathway inhi-
bitors LDN-193189 (LDN) (Cellagen technology) and
Dorsomorphin (DOR) (Abcam) were prepared using
DMSO and 10mM stocks stored at −20 °C. Inhibitors were
diluted in complete media as required. LDN interrupts the
BMP pathway through inhibiting AVCR1 (ALK2) and
BMPR1A (ALK3), receptor phosphorylation, whereas DOR
inhibits AVCR1 (ALK2), BMPR1A (ALK3), BMPR1B
(ALK6), thereby preventing phosphorylation of SMADs 1,
5 and 8, and transcription of downstream genes.
Trypan blue exclusion cell counts and XTT bioreduction
assay
Samples were diluted in Trypan Blue dye (Sigma-
Aldrich) of an acid azo exclusion medium by preparing a
1:1 dilution of the cell suspension using a 0.4% Trypan
Blue solution. Half maximal inhibitory concentration
(IC50) of each of the BMP pathway inhibitors and IM in
K562 cell line was established using XTT sodium 3′-[1-
[(phenylamino)-carbonyl]-3,4-Tetrazzolium]-bis(4-
methoxy-6-nitro) benzene sulphonic acid hydrate cell
proliferation assay (Sigma-Aldrich) according to man-
ufacturer’s instructions. The half maximal inhibitory
concentration (IC50) of each of the BMP pathway
inhibitors and IM were calculated using Prism software
(GraphPad Software).
Synergy studies using CalcuSyn
Synergy studies of either LDN or DOR in combination
with IM was performed using CalcuSyn (Biosoft). The
median-effect graph which is a plot of x= log (Dose of
drug) vs y= log (Fa) by the dose/the fraction unaffected
and dose–effect curve together with the combination
index (CI) ranges for these inhibitors was used to deter-
mine synergism in targeting CML cells. CalcySyn per-
forms multiple drug dose–effect calculations using the
median-effect methods described by T-C Chou and P.
Talalay65. The resulting combination index (CI) theorem
of Chou-Talalay was used to provide a quantitative deﬁ-
nition for additive effect (CI= 1), synergism (CI < 1), and
antagonism (CI > 1) in drug combinations.
Flow cytometry
For cell division analysis, CD34+ cells were stained with
the proliferation dye CellTrace™ Violet (Thermo Fisher)
and labelled with anti-CD34 (BD Biosciences), as
recommended by manufactures protocol. For establishing
a maximum point of ﬂuorescence staining, cells were
cultured in the presence of Colcemid (100 ng/mL, Invi-
trogen Life Technologies) to determine non-dividing cells
after labelling (CTV max). All primary CD34+ cells were
treated with IM, LDN, DOR or combinations in the
presence and absence of BMP4 and cultured as described
above in physiological growth factors or on the
HS5 stromal cells. Annexin V/7AAD (BD Biosciences)
staining was used to assess apoptosis by ﬂow cytometry
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using 1 × 105 cells per condition. Propidium iodide (PI)
staining buffer (BD Bioscience, Oxford, UK) was used to
assess cell cycle progression as per manufacturer’s pro-
tocol. To test for re-entry into cell cycle, cells were treated
with inhibitor concentrations as indicated for 24 h; cells
were then washed x5 with PBS prior to culture in com-
plete media for a further 24, 48 and 72 h and PI staining
performed. BMP pathway type I receptors and ALKs 2,
3 and 6 (R&D systems) were detected by intracellular ﬂow
cytometry according to the manufacturer’s instructions. A
list of antibodies used is provided in Table S2.
Fluorescence in situ hybridisation (FISH)
Detection of BCR-ABL fusion in CD34+ 38− CML cells
by FISH was performed as previously reported2.
Protein analysis and quantitative real-time polymerase
chain reaction
Whole cell lysates were prepared and SDS-PAGE western
blotting was performed as described previously2 using
PathScan Multiplex Western Cocktail primary antibody,
pCRKL (Cell Signalling Technology), SHPTP2 (Santa Cruz
Biotechnology), Anti-Phosphotyrosine Antibody, clone
4G10 and phospho-SMAD1/5/8 (Millipore). Immuno-
ﬂuorescent staining was performed on Poly-L-lysine slides,
cells were ﬁxed with 4% formaldehyde for 10min and
permeabilised with 0.5% Triton-X100 in PBS for 15min.
Following incubation with 5× blocking solution for 2 h,
proteins were detected using anti-SMAD4 (Millipore) and
phospho-SMAD1/5/8 primary antibodies overnight at 4 °C.
Following detection using the corresponding conjugated
secondary antibody, slides were then visualised under Zeiss
epiﬂuorescence microscope and images analysed using
AxioVision Rel.4.8 microscopy software. A list of antibodies
used is provided in Table S3. Quantitative real-time poly-
merase chain reaction (qRT-PCR) was undertaken using the
Fluidigm BioMark HD System and TaqMan (Applied Bio-
systems) gene expression assays, as per manufacturer’s
instructions. Eight low/medium copy number reference
genes were used in the analysis. A list of primers used is
provided in Table S4 with reference genes shaded in grey.
Assessment of hematopoietic progenitors
Colony-forming cell (CFC) assays were performed as
described by Holyoake et al.1 Overall, 4 × 103/mL cells
from each treatment arm were re-suspended in 300 µL
SFM and inoculated in 3mL Methocult H4034 (Stem Cell
Technologies). This was then split into two 35mM dishes
and incubated in a humidiﬁed incubator. CFCs were
counted on day 11.
Statistical analyses
Average responses from at least three independent
experiments are shown (mean ± SEM). Statistical analysis
was performed using GraphPad Prism 6 (GraphPad
Software Inc.), using Anova, Welch’s test, Student’s paired
t-test for matched samples, and Mann–Whitney U test for
unpaired samples.
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